Galera Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OQB
Galera Therapeutics, Inc. has entered into a definitive merger agreement with Obsidian Therapeutics, Inc. in an all-stock transaction expected to close by the third quarter of 2026.
OQB
Galera Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on February 24, 2025, to elect directors and ratify the appointment of its independent auditor.
OQB
Galera Therapeutics is seeking stockholder approval for a plan to liquidate and dissolve the company, following a strategic review and the cessation of clinical development.